FAKTOR-OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 15:16:52 2024-06-14 EDT | ||
| 7 EUR | -0.85% |
|
| Current month | -10.71% | ||
| 1 month | -21.17% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 7 | -0.85% |
| 24-06-13 | 7.06 | -0.84% |
| 24-06-12 | 7.12 | +2.30% |
| 24-06-11 | 6.96 | +0.43% |
| 24-06-10 | 6.93 | +1.02% |
Delayed Quote Börse Stuttgart
Last update June 14, 2024 at 03:16 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MG1VSZ |
| ISIN | DE000MG1VSZ0 |
| Date issued | 2024-04-08 |
| Strike | 718.6 $ |
| Maturity | Unlimited |
| Parity | 31.6 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.88 € |
|---|---|
| Lowest since issue | 6.77 € |
| Spread | 0.02 € |
| Spread % | 0.28% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
480.7
USD
Average target price
463.4
USD
Spread / Average Target
-3.60%
- Stock Market
- Certificates
- Certificat
